Inter Pharma Public Stock Current Valuation

IP Stock  THB 3.50  0.04  1.16%   
Valuation analysis of Inter Pharma Public helps investors to measure Inter Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
3.50
Please note that Inter Pharma's price fluctuation is slightly risky at this time. Calculation of the real value of Inter Pharma Public is based on 3 months time horizon. Increasing Inter Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Inter Pharma's intrinsic value may or may not be the same as its current market price of 3.50, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  3.5 Real  3.83 Hype  3.46
The intrinsic value of Inter Pharma's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Inter Pharma's stock price.
3.83
Real Value
6.04
Upside
Estimating the potential upside or downside of Inter Pharma Public helps investors to forecast how Inter stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Inter Pharma more accurately as focusing exclusively on Inter Pharma's fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimatedHigh
1.253.465.67
Details

Inter Pharma Public Company Current Valuation Analysis

Inter Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current Inter Pharma Current Valuation

    
  4.5 B  
Most of Inter Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inter Pharma Public is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, Inter Pharma Public has a Current Valuation of 4.5 B. This is 68.65% lower than that of the Healthcare sector and 3.08% lower than that of the Biotechnology industry. The current valuation for all Thailand stocks is 72.92% higher than that of the company.

Inter Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inter Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inter Pharma could also be used in its relative valuation, which is a method of valuing Inter Pharma by comparing valuation metrics of similar companies.
Inter Pharma is currently under evaluation in current valuation category among its peers.

Inter Fundamentals

About Inter Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inter Pharma Public's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inter Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inter Pharma Public based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Inter Stock

Inter Pharma financial ratios help investors to determine whether Inter Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Inter with respect to the benefits of owning Inter Pharma security.